Swiss National Bank Sells 14,500 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• Swiss National Bank reduced its stake in Elanco Animal Health by 1.5%, holding 957,792 shares worth approximately $10 million after selling 14,500 shares in the first quarter.
• Elanco reported a net margin of 9.68% and a revenue of $1.24 billion in its latest quarterly earnings, surpassing analyst expectations and reflecting a year-over-year revenue increase of 4.8%.
• Analysts have optimistic projections for Elanco’s stock, with a consensus rating of "Moderate Buy" and an average target price of $17.33, following multiple upward revisions from various research firms.

Swiss National Bank trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 1.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 957,792 shares of the company's stock after selling 14,500 shares during the quarter. Swiss National Bank owned approximately 0.19% of Elanco Animal Health worth $10,057,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Dimensional Fund Advisors LP lifted its holdings in shares of Elanco Animal Health by 6.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after purchasing an additional 1,074,274 shares during the last quarter. Shapiro Capital Management LLC lifted its holdings in shares of Elanco Animal Health by 7.5% during the fourth quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock valued at $149,640,000 after purchasing an additional 862,900 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Elanco Animal Health by 8.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 6,924,098 shares of the company's stock valued at $83,851,000 after purchasing an additional 538,631 shares during the last quarter. Douglas Lane & Associates LLC lifted its holdings in shares of Elanco Animal Health by 5.6% during the first quarter. Douglas Lane & Associates LLC now owns 3,895,190 shares of the company's stock valued at $40,899,000 after purchasing an additional 205,241 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Elanco Animal Health by 22.5% during the fourth quarter. Northern Trust Corp now owns 2,943,686 shares of the company's stock valued at $35,648,000 after purchasing an additional 541,341 shares during the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

NYSE:ELAN traded up $0.0450 during trading hours on Thursday, reaching $17.5050. The company had a trading volume of 6,855,970 shares, compared to its average volume of 6,544,357. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.08. The firm has a market cap of $8.70 billion, a price-to-earnings ratio of 20.35, a PEG ratio of 3.24 and a beta of 1.66. The firm's 50 day moving average price is $15.00 and its 200-day moving average price is $12.42.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the firm posted $0.30 EPS. The firm's revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. UBS Group boosted their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Finally, Piper Sandler boosted their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $17.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.